The following information is missing from the Competing Interests statement:
Dr. Harald Matthes is a member of the board of directors at Weleda AG, a company that until 2016 distributed Iscador, a mistletoe preparation. In addition, Dr. Harald Matthes is a member of the board of the Hufelandgesellschaft e. V. in Germany; President of the DAHN (German Academy for Homeopathy and Naturopathy); and medical director and managing director of Gemeinschaftskrankenhaus Havelhöhe, a hospital for anthroposophic medicine. Dr. Harald Matthes is also a recipient on an endowed professorship from Charité in Berlin on Integrative and Anthroposophical Medicine. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Reference
- 1. Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, et al. (2018) Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE 13(8): e0203058. https://doi.org/10.1371/journal.pone.0203058 pmid:30148853
Citation: Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, et al. (2022) Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE 17(8): e0273387. https://doi.org/10.1371/journal.pone.0273387
Published: August 16, 2022
Copyright: © 2022 Schad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.